Sweeteners
aspartame increases cancer risk
Contested Sweeteners 💰 Industry COI noted🔬 Includes disconfirming
Part of: • aspartame
RefutedContestedStrong support
consensus score 0.07
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
6 support 3 contradict 0 tested null 2 mixed · 11 sources, 9 independent groups
What the evidence shows
Contested — the human evidence splits, and none of it is a controlled test. IARC (2023) classed aspartame Group 2B ('possibly carcinogenic', limited evidence), a hazard flag rather than a quantified risk. Against a link: the Nurses' Health Studies found no breast-cancer association (HR 1.
The evidence (24)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Pavanello S, Moretto A, La Vecchia C, Alicandro G 2023 · Regul Toxicol Pharmacol | observational | contradicts | moderate | Tox + epi review incl. aspartame genotoxicity/carcinogenicity data: no evidence of cancer risk. |
| Boon D, Marchitti SA, Colonna KJ, Chowdhury-Paulino IM, Li W, Berky A, Restrepo C, Jack M, Goodman JE 2025 · Advances in nutrition (Bethesda, Md.) | observational | contradicts | moderate | Systematic review (preregistered, OSF) of 90 epidemiology studies covering 6 non-sugar sweeteners (incl. aspartame) and 17 cancer types through Fall 2024; found no consistent associations between any NSS and any cancer type and no dose-resp |
| Huang C, Wei L, Yuan W, Lu Y, Zhang G, Yan Z 2025 · International journal of molecular sciences | mechanism | mixed | low | Network toxicology/molecular docking analysis (TCGA differential expression + in-silico target intersection) proposes 8 core genes (e.g. EDNRA) linking aspartame to kidney renal papillary cell carcinoma; no wet-lab or epidemiological valida |
| Li H, Zhang Y, He Y, Huang J, Yao J, Zhuang X 2024 · Br J Nutr | meta-analysis | mixed | moderate | MA of 12 observational studies on sweeteners and endometrial cancer. Non-nutritional sweeteners ('such saccharin and aspartame') pooled across 4 studies: OR 0.90 (95% CI 0.81 to 1.01) - no aspartame-specific estimate. Nutritive sweeteners (sugars) OR 1.25 (1.14 to 1.38; 11 studies). Pooled exposure, off-scope for aspartame. |
| Li NR, Zeng YX, Gu YF, Xie P, Deng BY, Lu SF, Li WA, Liu Y 2025 · Ecotoxicology and environmental safety | mechanism | supports | low | Network toxicology + Mendelian randomization + molecular docking/dynamics study proposes aspartame promotes liver cancer via CASP1 (strongest docking affinity -18.45 kJ/mol); MR used to prioritize causal target genes (CASP1 among them) rath |
| Gong Q, Liang D, Luo Y, Yang C, Yang Y, Zhang S 2026 · Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association | observational | supports | moderate | Mendelian randomization found genetically predicted aspartame intake associated with increased ovarian cancer risk (OR 2.10, 95% CI 1.06-4.18); in vitro validation showed aspartame promoted malignant phenotypes in OC cell lines via AURKA/CC |
| Doueihy NE, Ghaleb J, Kfoury K, Khouzami KK, Nassif N, Attieh P, Ghadieh HE, Azar S, Kanaan A, Harb F 2025 · Journal of xenobiotics | observational | mixed | low | Narrative mini-review of in vitro, in vivo, and epidemiological studies on aspartame carcinogenicity; concludes results are inconsistent, with some studies suggesting an association with high intake and others finding none. |
| Yan S, Yan F, Liu L, Li B, Liu S, Cui W 2022 · Nutrients | meta-analysis | supports | low | MA: aspartame subgroup showed a significant cancer association in some analyses, though overall artificial-sweetener effect was null. |
| d10-1093-toxres-tfag049 2026 · Toxicology Research | mechanism | supports | low | Network toxicology + machine learning + molecular docking study intersecting aspartame targets with thyroid-cancer-associated genes (GEO datasets); identifies CTSC, ECE1, F10, HMGCR, APLNR as predictive features with stable docking to aspar |
| Zhu X, Welsh JA, McCullough ML, Sylvetsky AC, Hartman TJ, Patel AV, Deubler EL, Ferranti EP, Um CY 2026 · J Nutr | observational | mixed | moderate | Large prospective cohort: aspartame–cancer evidence inconsistent, particularly for obesity-related cancers. |
| Hong QY, Huang Y, Yang J, Su LT, Dai ZR, Zhao CF 2025 · Current research in food science | observational | supports | low | Broad narrative review of sweeteners' metabolic and cancer effects over the past three decades; concludes excessive/long-term use of 'certain sweeteners' may be associated with malignant tumor occurrence, alongside cardiovascular and metabo |
| Shaher SAA, Mihailescu DF, Amuzescu B 2023 · Nutrients | observational | mixed | low | Aspartame safety review: epi signals for NHL/myeloma in males; carcinogenicity debate ongoing, chance not excluded. |
| Crick DCP, Liu W, Hwang LD 2026 · Public Health Nutr | observational | tested-null | low | Two-sample Mendelian randomisation: 6 SNP instruments for perceived intensity of aspartame (GWAS of 1,757 Australian adolescents) against 21 site-specific cancers in IEU OpenGWAS/FinnGen and UK Biobank. Only signal: cervical cancer OR 0.998 (0.997-0.999) per SD of perceived intensity, which attenuated to null in multivariable MR. The authors say the instruments 'were based on perceived intensity of artificial sweeteners rather than actual preference or consumption', and suggest higher perception may even lower intake, so this is a proxy for the exposure with unknown sign. |
| Romanos-Nanclares A, Schernhammer E, Willett WC, Holmes MD, Chen WY, Eliassen AH 2025 · J Natl Cancer Inst | observational | contradicts | high | Nurses' Health Studies: no aspartame–breast-cancer association (HR 1.00 per 200 mg/d), robust to lag analyses. |
| Debras C, Chazelas E, Srour B, Druesne-Pecollo N, Esseddik Y, Szabo de Edelenyi F, Agaësse C, De Sa A, Lutchia R, Gigandet S, Huybrechts I, Julia C, Kesse-Guyot E, Allès B, Andreeva VA, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M 2022 · PLoS Med | observational | supports | moderate | NutriNet-Santé: aspartame intake associated with slightly higher overall cancer risk (notably breast and obesity-related cancers). |
| Abu-Zaid A, Kutbi E, Alshammari N, AlJurayyan AN, Adly HM, Saleh SAK, Baradwan S, Jamal M, Peer-Zada F, Mohamed S, Syed H, Ahmed RS, Abuzaid M, Alomar O 2025 · Frontiers in medicine | meta-analysis | contradicts | moderate | Umbrella review of 10 meta-analyses (35 datasets) through Jan 2025: 'Overall, artificial sweetener intake was not significantly associated with cancer risk (RR: 0.99; 95% CI: 0.96–1.01).' The authors state directly that 'This finding reflects the effect of various sweeteners grouped together and should not be extrapolated to individual compounds.' Confirmed in Discussion: 'Another important limitation of this umbrella review is the inability to perform subgroup analyses by specific artificial sweetener types (e.g., aspartame, sucralose, saccharin) ... none of the included meta-analyses provided disaggregated results based on individual sweeteners.' No aspartame-specific estimate exists anywhere in this paper. (By cancer type, the one significant subgroup was gynecological cancers, RR 0.87, 95% CI 0.79–0.96 — also class-level, not compound-specific.) |
| Marchitti SA, Boon D, Jack M, Goodman JE 2025 · Adv Nutr | animal | contradicts | moderate | Narrative review (ABA-funded; authors employed by Gradient/ABA), not a meta-analysis: 'a comprehensive review of the available experimental evidence from animal and mechanistic studies'. For aspartame: 'the weight of evidence supports the conclusions previously reached by United States FDA, EFSA, and JECFA that aspartame lacks both genotoxic and carcinogenic potential.' Pools nothing - review, zero weight. |
| Haighton L, Roberts A, Jonaitis T, Lynch B 2019 · Regul Toxicol Pharmacol | observational | contradicts | moderate | Quality-appraised aspartame cancer epidemiology: does not support an increased cancer risk in humans. |
| Chen HP, Kao Y, Lin MW, Lee CT, Wu HT, Kuo HY 2025 · Nutrients | observational | mixed | low | Narrative review of low-calorie sweeteners' metabolic, glycemic, cardiovascular, carcinogenic and gut-microbiota effects; states carcinogenicity concerns are among 'potential risks' but calls for more long-term high-quality trials without n |
| Watling CZ, Zhao L, Zhang X, Deubler E, Gonzalez-Feliciano AG, Graubard BI, Petrick JL, Wojt A, Butera G, Hofmann JN, Beane Freeman LE, Shrubsole MJ, Zheng W, Sudenga SL, Schernhammer E, Eliassen AH, Mucci LA, Sesso HD, Sinha R, Loftfield E, Um CY, McCullough ML, Jenab M, Zhang X, McGlynn KA 2026 · JAMA Netw Open | observational | contradicts | moderate | Pooled analysis of 11 prospective cohorts (10 US, 1 European; n=1,518,411; 2,811 liver cancers). Exposure is artificially sweetened beverages as a class: 'we estimated total ASB intake as the sum of reported intake of diet cola or soda and other low-calorie sweetened beverages'. 'After multivariable adjustment, ASB intake per 1-beverage/day increase was not associated with liver cancer risk, HCC (10 cohorts), or ICC (6 cohorts)' (ICC HR 1.04, 0.94-1.14; the adjusted overall HR is in Figure 1, not in the text). Unadjusted for BMI/diabetes, ASB was positive (HR 1.11, 1.07-1.15). The authors note IARC 'used intake of ASB as a proxy for aspartame' and extrapolate ('more specifically aspartame and HCC, is not strongly supported'), but no aspartame-specific intake or estimate exists. Pooled exposure, off-scope, matching sibling rows s37424288, s37918372 and s40988757. |
| Meng K, Bao Y, Chen G, Qu J, Liang S, An S, Chen Y, Liu X, Fu X 2025 · Scientific reports | animal | contradicts | low | Mouse glioblastoma model with dietary aspartame: metagenomics/transcriptomics showed aspartame did not significantly affect tumor growth, though it altered gut microbiota composition (decreased Rikenellaceae) and upregulated m6A-regulated o |
| Yang H, Liu Y, Peng J, Mao X, Zhang Y, Chen S, Sun G, Zhu L, Zhao Y 2025 · Medicine (Baltimore) | observational | mixed | moderate | Two-sample MR, 15 cancers. Exposure instruments are UK Biobank GWAS of 'intake of AS in cereals, coffee, and tea' (64,949 Europeans) - artificial sweeteners as a class, with no aspartame-specific instrument or estimate. IVW results point both ways across sites, e.g. 'outcome ovarian cancer IVW: OR = 1.015, 95% CI = 1.005–1.025, P = .004' and 'outcome gastric cancer IVW: OR = 0.321, 95% CI = 0.131–0.787, P = .013'; no multiple-testing correction ('multiple correction tests were not performed'). Off-scope: pooled sweetener exposure, would vote identically on any other sweetener - consistent with the class-level siblings s42268607, s37424288, s37918372, s40988757. |
| Zhu C, Ji D, Ma J, Da M 2024 · Oncology | meta-analysis | mixed | moderate | MA of 10 observational studies (711,537 participants): 'the intake of ASs reduced the incidence of CRC (OR = 0.93, 95% CI = [0.87-0.99])'; low dose OR 0.90 (0.83-0.99), medium 1.11 (0.93-1.33), high 0.89 (0.79-1.00). Estimates are for ASs pooled; no aspartame-specific result in the abstract. Pooled exposure, off-scope. |
| Zhu Y, Zhu J, Hu Z, Jin J, Zhou J, Yang Y, Wang Y, Peng J, Chai X, Chen G, Zhou W, Sheng J 2026 · Journal of hazardous materials | animal | supports | moderate | Apc(min/+) mouse model (subchronic aspartame exposure, 3 months) showed increased proportion of medium-sized small-intestinal tumors vs control, mediated via gut microbiota (A. muciniphila) and serotonin pathway. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.